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ABSTRACT
Decapping enzymes are required for the removal of
the 50-end
m7GpppN cap of mRNAs to allow their
decay in cells. While many cap-binding proteins rec-
ognize the cap structure via the stacking of the
methylated guanosine ring between two aromatic
residues, the precise mechanism of cap recognition
by decapping enzymes has yet to be determined.
In order to get insights into the interaction of
decapping enzymes with the cap structure, we
studied the vaccinia virus D10 decapping enzyme
as a model to investigate the important features
for substrate recognition by the enzyme. We dem-
onstrate that a number of chemically modified
purines can competitively inhibit the decapping
reaction, highlighting the molecular features of the
cap structure that are required for recognition by
the enzyme, such as the nature of the moiety at pos-
itions 2 and 6 of the guanine base. A 3D structural
model of the D10 protein was generated which
suggests amino acids implicated in cap binding.
Consequently, we expressed 17 mutant proteins
with amino acid substitutions in the active site of
D10 and found that eight are critical for the
decapping activity. These data underscore the func-
tional features involved in the non-canonical
cap-recognition by the vaccinia virus D10 decapping
enzyme.
INTRODUCTION
The synthesis, translation and decay of messenger RNAs
(mRNAs) are highly regulated processes in cells (1–3). In
order to allow mRNA turnover, the protective structures
found on both the 50- and 30-ends of mRNAs have to be
removed. mRNA decay occurs mainly in the cytoplasm by
the recruitment of a plethora of enzymes involved in deg-
radation. While mRNA decay has previously been
associated with P-bodies, recent evidences suggest that
the initiation of decapping is independent of P-body for-
mation, and that the latter would rather be a consequence
of mRNA decay (4–6). The
m7GpppN cap structure found
at the 50-end of mRNAs is degraded by decapping
enzymes that have now been identiﬁed in mammalians,
plants, and yeasts (Dcp2 proteins), as well as in some
viruses (vaccinia virus and African swine fever virus)
(7–13). The Dcp2 and viral decapping enzymes exhibit a
speciﬁc hydrolase activity resulting in cleavage between
the a- and b-phosphates of the
m7Gp
gp
bp
aN cap to
generate both
m7GDP and monophosphorylated RNA
products. The remaining monophosphorylated mRNAs
are then further subjected to 50!30 exonucleolytic degrad-
ation (14,15). Decapping enzymes possess a conserved
NUDIX motif common to Dcp2 and viral decapping en-
zymes as well as other hydrolases members of the NUDIX
hydrolase superfamily (7–9,16,17). The conserved 23
amino acids NUDIX motif GX5EX7REUXEEXGU
(where U is a bulky hydrophobic amino acid and X is
any amino acid) has previously been demonstrated to be
required for catalysis during the decapping reaction
(8,18,19).
The cellular mRNA 50 cap structure is recognized by a
number of cap-binding proteins other than the decapping
enzymes. Structural studies of the interaction of cap de-
rivatives with the human cap-binding complex (CBC), the
mouse eIF4E translation initiation factor, and the vaccinia
virus VP39 mRNA 20-O-methyltransferase, revealed that
cap-recognition is primarily achieved by the stacking of
the methylated guanosine ring between two aromatic
residues within the catalytic center of these proteins
(20–23). These evolutionarily unrelated proteins have
evolved to share a canonical cap-recognition mode. In
contrast, the recently published crystal structures of
the yeast Schizosaccharomyces pombe Dcp2 enzyme
(SpDcp2) indicated that no aromatic residues are found
*To whom correspondence should be addressed. Tel: +11 819 564 5287; Fax: +11 819 564 5340; Email: martin.bisaillon@usherbrooke.ca
Published online 17 July 2010 Nucleic Acids Research, 2010, Vol. 38, No. 21 7599–7610
doi:10.1093/nar/gkq628
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.in the vicinity of the cap-binding site of the enzyme
(10,24). So far, no mechanism has been proposed for the
cap-recognition mode of metazoan or viral decapping
enzymes. However, structural data and mutational
analysis of the yeast decapping enzyme highlighted the
presence of amino acids located in the catalytic pocket,
such as Lys129 and Gln169, that could potentially be
involved in recognition of the cap structure (10).
The discovery that mammalian viruses can harbor
decapping enzymes has important implications for the
control of viral and cellular gene expression. The
vaccinia virus D10 decapping enzyme (D10) is expressed
during late viral transcription, and deletion of the D10
gene was shown to produce a 10-fold reduction of the
speciﬁc infectivity of the vaccinia virions (25). The
presence of decapping enzymes in vaccinia virus is sug-
gested to be required to eliminate competing host
mRNAs and to allow stage speciﬁc synthesis of viral
proteins (7). Previous studies have further demonstrated
the ability of the D10 decapping enzyme to hydrolyze
capped RNAs of at least 24nt in length in the presence
of divalent cations. Notably, the decapping reaction
catalyzed by D10 was also shown to be inhibited by
methylated cap analogs such as
m7GpppG and
m7GTP
(7,26). With no available crystal structure for D10, we
previously generated a structural model of the tertiary
structure of the active site of the D10 protein based on
the SpDcp2 3D structure (26). Our biochemical assays
also demonstrated that the D10 protein utilizes a
two-metal ion mechanism for catalysis. The importance
of Glu132 and Glu145 in metal ion coordination, as well
as Glu141 in the positioning of a water molecule in the
catalytic center was also highlighted by this study (26).
In order to gain additional insights into the molecular
determinants involved in substrate recognition by the
vaccinia virus D10, we now perform a thorough probing
of the active site of the enzyme using a collection of nu-
cleotide analogs. Moreover, mutagenesis studies underline
the importance of speciﬁc amino acids located within the
catalytic pocket of D10 for the decapping activity. Using
this combination of nucleotide analogs and site-directed
mutagenesis, this study illustrates the speciﬁc functional
groups that are required for the non-canonical
cap-recognition mode of the D10 decapping enzyme.
MATERIALS AND METHODS
Homology modeling
The crystal structure of the S. pombe decapping enzyme
[SpDcp2, amino acids 1–266 (10)] was used as a template
to model the vaccinia virus D10 protein (amino acids
1–226). The atomic coordinates were obtained from the
Protein Data Bank ﬁle 2A6T. The predicted 3D structure
of the D10 protein was generated with the Deep View
program (27). The coordinates of the amino acids from
the D10 protein sequence that were not folded by the
program were deleted from the generated PDB ﬁle to
produce a workable ﬁle for the modelized D10 structure.
The modiﬁed D10 PDB ﬁle was then uploaded in the
Visual Molecular Dynamics program (28) to generate
the presented structures.
Molecular docking
Docking calculations were carried out using the Docking
Server software and the Dreiding force ﬁeld was used for
energy minimization of N7-methyl diguanosine
triphosphate (
m7GpppG) using built-in Chemaxon tools
in Docking Server (29). PM6 semi-empirical charges
calculated by MOPAC2007 were added to the ligand
atoms. Non-polar hydrogen atoms were merged and rotat-
able bonds were deﬁned (30). Docking calculations were
carried out using the SpDcp2 crystal structure (Protein
Data Bank 2A6T). Essential hydrogen atoms, Kollman
united atom type charges and solvation parameters were
added with the aid of AutoDock tools (31). Afﬁnity (grid)
maps of 20 20 20A ˚ grid points and 0.375A ˚ spacing
were generated using the Autogrid program (31).
AutoDock parameter set- and distance-dependent dielec-
tric functions were used in the calculation of the van der
Waals and the electrostatic terms, respectively. Docking
simulations were performed using the Lamarckian
genetic algorithm and the Solis and Wets local search
method (32). Initial position, orientation, and torsions of
the ligand molecules were set randomly. Each docking ex-
periment was derived from two different runs that were set
to terminate after a maximum of 2500000 energy evalu-
ations. The population size was set to 150. During the
search, a translational step of 0.2A ˚ , and quaternion and
torsion steps of 5A ˚ were applied.
D10 expression, puriﬁcation and decapping activity
The wild-type D10 protein and the substitution mutants
were expressed and puriﬁed as described earlier (26).
Reaction mixtures (10ml) containing 10mM Tris–HCl
(pH7.5), 100mM KOAc, 10mM MnCl2, 10mM MgCl2,
1mM DTT, 0.9mM g-phosphate-labeled 7-methyl-capped
RNA substrate and 1mM puriﬁed D10 WT or mutant
protein were incubated for 15min at 25 C. The reactions
were quenched by adding 1ml of 50mM EDTA. Aliquots
of the mixtures were applied to a polyethyleneimine–cel-
lulose TLC plate, which was developed with 0.5mM LiCl
and 1M methanoic (formic) acid. The release of
g-phosphate-labeled
m7GDP was revealed by autoradiog-
raphy with a Storm phosphoimager (Amersham
Biosciences) and quantiﬁed using ImageQuant 5.0
(Molecular Dynamics). The average of at least two
single independent experiments is presented.
N7-Methyl-capped RNA synthesis
A radiolabeled 81-mer RNA substrate was synthesized
and capped as described earlier (26).
Inhibition assays
Reaction mixtures (10ml) containing 10mM Tris–HCl
(pH7.5), 100mM KOAc, 10mM MnCl2, 10mM MgCl2,
1mM DTT, 0.9mM g-phosphate-radiolabeled N7-methyl-
capped RNA substrate and 2.5mM puriﬁed D10 WT
protein were incubated for 15min at 25 C in the
7600 Nucleic Acids Research, 2010,Vol.38, No. 21presence 100mM of various GTP analogs. The reactions
were quenched by adding 1ml of 50mM EDTA and
applied to a polyethyleneimine–cellulose TLC plate,
which was developed with 0.5mM LiCl and 1M
methanoic (formic) acid. The average of at least two
single independent experiments is presented. Inhibition
assays were performed in the presence of increasing con-
centrations of nucleotide analogs, while competitive inhib-
ition was assessed by performing decapping assays with
methylated-capped RNA concentrations ranging from
0t o1 mM in the presence of 0, 50, 100 or 200mMo f
GTP. The Ki values were determined using the following
equation:
Ki¼
IC50
ð1+ð½S =KmÞÞ
where [S] represents the concentration of N7-methyl-cap
RNA in the reaction mixture.
Circular dichroism spectroscopy measurements
Circular dichroism measurements were performed with a
Jasco J-810 spectropolarimeter. The samples were
analyzed in quartz cells with path lengths of 1mm.
Far-UV wavelength scans were recorded from 200 to
260. The average of three wavelength scans is presented.
The ellipticity results were expressed as mean residue
ellipticity, in millidegrees (mdeg).
RESULTS
Probing of the D10 enzyme active site with
nucleotide analogs
With the intention of probing the active site of the
vaccinia virus D10 decapping enzyme with nucleotide
analogs, we ﬁrst veriﬁed if the activity of a recombinant
His-tagged version of the enzyme could be inhibited
in vitro by GTP. All the decapping assays were performed
at sub-optimal conditions in order to account for the
possible increase in decapping activity that could poten-
tially result from the addition of nucleotide or nucleotide
analogs in solution. The addition of increasing GTP con-
centrations to the reaction resulted in a decrease in the
generation of the
m7GDP decapping reaction product
(Figure 1A and B). This concentration-dependent inhib-
ition was also observed in the presence of ATP, however
to a lower extent (Figure 1B). Further characterization
demonstrated that both the GTP and ATP inhibitions
are competitive, suggesting that the purine base binds to
the active site of the viral decapping enzyme. A
lineweaver–burk representation of the competitive inhib-
ition data obtained for GTP is presented in Figure 1C.
Furthermore, derivation of binding data of GTP to the
D10 protein with the Scatchard equation yielded a linear
plot consistent with a single binding site for the GTP
molecule on the enzyme (data not shown). It should be
noted that no inhibition was observed in the presence of
either CTP or UTP (data not shown).
In order to gain insights on the molecular determinants
involved in substrate binding, we then tested a collection
of 26 analogs of ATP and GTP for their ability to inhibit
the decapping reaction catalyzed by the D10 protein. The
purine analogs selected display various modiﬁcations on
both the ribose and the guanine or adenine base
(Figure 2A). The modiﬁcations ranged from relatively
minor (modiﬁcation of a single functional group) to
severe (modiﬁcation of multiple functional groups). The
informative ﬁnding is that a number of analogs were able
to efﬁciently inhibit the reaction at a concentration of
100mM (Figure 2B, Table 1). For instance, the presence
of 100mM 2-methyl-oxo-GTP inhibited the decapping
activity of D10 by 75%, while the addition of xanthosine
triphosphate (XTP) to the decapping reaction did not
inhibit the activity of the enzyme (Figure 2B). All
analogs tested in the current study were competitive in-
hibitors of the decapping reaction, indicating that they
bind to the active site of the enzyme. A typical inhibition
example using N1-methyl-ATP is presented in Figure 2C.
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Figure 1. Competitive inhibition of the RNA decapping activity of D10 by GTP. (A) The D10 protein (2.5mM) and N7-methyl-cap RNA substrate
(0.9mM) were incubated in 10mM Tris–HCl (pH 7.5), 100mM KOAc, 1mM DTT, 10mM MgCl2 and 10mM MnCl2 (decapping buffer) for 15min
at 25 C with increasing concentrations of GTP (10, 20, 50, 100, 200, 500 and 1000mM). The reactions were stopped by the addition of EDTA to
50mM. The products were analyzed by TLC on a polyethyleneimine-cellulose plate and developed with 0.5M LiCl and 1M formic acid. An
autoradiogram of the plate is shown. The positions of the unlabeled products, visualized under ultraviolet light, are indicated. (B) Dose–response
inhibition of the decapping activity. The mean values of three replicates with standard errors are presented for the inhibition of the decapping
reaction observed in the presence of both GTP (ﬁlled square) and ATP (unﬁlled square). (C) Competitive inhibition of the decapping reaction by
GTP. Double-reciprocal plot of the inhibition of cap hydrolysis by D10 in the presence of 0mM (ﬁlled square), 50mM (ﬁlled triangle), 100mM
(unﬁlled circle), 200mM (unﬁlled diamond) of GTP in solution. A close-up view of the data is shown in inset.
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for the various analogs that were able to reduce the
decapping activity by at least 25% (Table 1). It should
be noted that although UTP and CTP are not potent in-
hibitors of the decapping reaction, various CTP and UTP
analogs (e.g. 5-methyl-UTP, 5-methyl-CTP, UDP, CDP)
were also tested for their potential ability to inhibit the
decapping reaction by the vaccinia virus D10. Our results
demonstrate that these UTP and CTP analogs were
unable to affect the activity of the enzyme (data not
shown).
These data indicate that the active site of D10 is ﬂexible
and can accommodate a number of chemically modiﬁed
purines. The analogs harboring chemical modiﬁcations on
the ribose moiety and the purine rings (Figure 2A) helped
to illuminate the ﬂexibility of the D10 active site. As sug-
gested by a previous study (7), the presence of a methyl
group on the N7 position greatly increased the inhibitory
potential of GTP and GDP (Table 1), highlighting the
importance of this position for recognition by D10
(Figure 2D). In fact, the decapping activity was completely
abolished in the presence of 100mM
m7GTP. Moreover,
we initially suspected that the ability of the 6-oxo group of
GTP (which is substituted by a 6-amino group in ATP) to
act as a hydrogen-bond acceptor might be a key determin-
ant promoting an increase in the inhibitory potential of
GTP over ATP. The inhibitory properties of three GTP
analogs harboring chemical modiﬁcations at this position
provided clues on the importance of this functional group.
Replacement of the 6-oxo group of GTP by SCH3
(6-methyl-thio-GTP) or OCH3 (6-methyl-oxo-GTP), that
both maintain the capacity to act as hydrogen-bond ac-
ceptors, had a strong negative effect on the inhibition of
the decapping activity in comparison to GTP, with IC50
and Ki values >200 and 0.80mM, respectively (Table 1).
These initial results suggest that the addition of the bulkier
Figure 2. Inhibition of the RNA decapping activity by nucleotide analogs. (A) Representation of the purine analogs tested. (B) Inhibition of the
decapping reaction in the presence of 100mM of selected nucleotide analogs (0.9mM capped RNA, 1mM D10, 50mM Tris–HCl, 10mM MgCl,
10mM MnCl and 5mM DTT). Inhibition parameters are compiled in Table 1. (C) Competitive inhibition with N1-methyl ATP. Double-reciprocal
plot of the inhibition of cap hydrolysis by D10 in the presence of 0mM (ﬁlled square), 50mM (ﬁlled triangle), 100mM (unﬁlled circle) of
N1-methyl-ATP in solution. (D) Representation of the important functional features of the GTP molecule required for the inhibition of the
decapping reaction.
7602 Nucleic Acids Research, 2010,Vol.38, No. 21methyl group at position 6 weakens the ability of the
analog to bind to the D10 protein. However, we
observed that the substitution of the 6-oxo group of
GTP by a thiol group (6-thio GTP), which lacks
hydrogen bond acceptor properties, also severely
decreased the inhibitory potential of the molecule
(Table 1). We therefore conclude that the presence of a
functional group which can display hydrogen-bond
acceptor properties is important at the C6 position of
the substrate (Figure 2D).
Another key difference between GTP and ATP is the
nature of the functional group located at the C2 position
of the purine rings. GTP displays a 2-amino group with
hydrogen-bond donor properties while this functional
group is absent from ATP. The importance of the
hydrogen-bond at this position is elegantly highlighted
by inhibition studies performed with XTP, which only
differs with GTP by harboring a 2-oxo group at this
position (instead of the 2-amino group). The replacement
of the hydrogen-bond donor group by a hydrogen-bond
acceptor group drastically reduced the inhibitory potential
of this analog, demonstrating its importance for substrate
recognition. These results clearly indicate the importance
of a hydrogen-bond donor group at this position of the
substrate. This ﬁnding is supported by inhibition studies
performed with ribavrin triphosphate, a GTP analog that
completely lacks the C2 and C3 positions of the purine
rings. This analog had a weak ability to inhibit the
decapping reaction with IC50 and Ki values >200 and
0.80mM, respectively (Table 1).
Analogs harboring substituents at the C8 position of the
guanine base (8-bromo-GTP, 8-iodo-GTP and
8-oxo-GTP) did not efﬁciently inhibit the decapping
reaction, as reﬂected by their high IC50 and Ki values
(Table 1). We postulate that the addition of these substitu-
ents likely results in steric hindrance with active site
residues, thereby limiting the access of these analogs to
the active site of the D10 protein. This suggests that the
C8 position likely resides in close proximity to amino acis
located in the D10 active site. In contrast, the addition of a
methyl group to the N1 position of adenine had no sig-
niﬁcant effect on the inhibition of the decapping activity.
The analog harboring such a modiﬁcation (N1-methyl
ATP) was not a very potent inhibitor of the enzyme
(Table 1), indicating that the enzyme does not make
critical interaction with the substrate through this
position.
Although the current analysis largely focuses on the
importance of speciﬁc molecular determinants of the
purine rings required for substrate recognition, some of
the analogs contained modiﬁcations on the ribose
moiety of the nucleotide analogs. Surprisingly, all GTP
and ATP analogs harboring various modiﬁcations/substi-
tutions on the ribose moieties were potent inhibitors of the
decapping reaction. As seen from the inhibition param-
eters, the removal of the 20-OH group (20-dGTP and
20-dATP) had no signiﬁcant effect on the inhibition of
the decapping activity. Most strikingly, 20,30-dATP
which lacks both ribose hydroxyls was still able to signiﬁ-
cantly inhibit the decapping reaction. Similarly, the
addition of substituents on the ribose hydroxyls did not
alter the ability of analogs to inhibit the decapping
reaction. 20-methyl-oxo-GTP and 30-methyl-oxo-GTP in-
hibited the reaction with Ki values of 0.11 and 0.26mM,
respectively. We conclude that the binding of the substrate
to the vaccinia virus D10 protein does not involve signiﬁ-
cant interactions with the ribose hydroxyls.
Moreover, we evaluated the ability of guanine and
GMP to inhibit the decapping reaction. These two mol-
ecules did not affect the decapping reaction, as evidenced
by their high IC50 and Ki values (Table 1). In addition,
pyrophosphate and tripolyphosphate were also unable to
inhibit the decapping activity of D10 (data not shown).
From these data, we infer that a minimum of two phos-
phates linked to a purine base is required for interaction
with the vaccinia virus D10 protein (Figure 2D).
Docking of m7GDP to SpDcp2
While no crystal structure is yet available for the vaccinia
virus D10 protein, the crystal structure of the S. pombe
Dcp2 (SpDcp2) decapping enzyme has been resolved
(10,24). We previously utilized this latter structure to
generate a model of the active site of D10 using the
Deep View bioinformatics software (26,27). Since the pre-
dicted D10 catalytic center structure was shown to be
similar to that of SpDcp2, we now utilized the SpDcp2
Table 1. Parameters for the inhibition of the decapping activity of
D10 by nucleotide analogs
Nucleotide analog Relative decapping
activity (%)
(100mM analog)
a
IC50 (mM) Ki (mM)
None 100
GTP 35±8 22 0.09
Guanine 92±4 >200 >0.80
GMP 94±4 >200 >0.80
GDP 69±11 171 0.68
N7-methyl-GDP 24±7 21 0.08
N7-methyl-GTP 3±1 3 0.01
N7-methyl-GpppG 36±5 69 0.28
6-thio-GTP 83±5 >200 >0.80
6-methyl-thio-GTP 95±2 >200 >0.80
6-methyl-oxo-GTP 78±5 >200 >0.80
8-bromo-GTP 76±5 >200 >0.80
8-iodo-GTP 95±2 >200 >0.80
8-oxo-GTP 80±2 >200 >0.80
20-deoxy-GTP 22±7 27 0.11
20-methyl-oxo-GTP 25±5 27 0.11
30-methyl-oxo-GTP 41±12 65 0.26
XTP 97±1 >200 >0.80
Ribavirin triphosphate 96±3 >200 >0.80
ATP 65±6 84 0.34
ADP 74±1 188 0.75
20-deoxy-ATP 63±5 129 0.51
20-30-dideoxy-ATP 67±8 166 0.66
20-ﬂuoro-ATP 76±5 >200 >0.80
N6-methyl-ATP 92±4 >200 >0.80
N1-methyl-ATP 60±10 175 0.7
6-methyl-thio-ITP 95±1 >200 >0.80
aThe decapping assays were performed a minimum of three times sep-
arately. Results are shown as the means of these independent experi-
ments and normalized to the speciﬁc activity observed in the absence of
nucleotide analog.
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mation on the interaction between the decapping enzyme
and the
m7GpppG moiety. Extensive computational
docking and structure optimizations were used to
generate a model of the
m7GpppG-enzyme complex.
More than 2000000 energy evaluations were performed
in order to provide an accurate description of the enzyme–
substrate interactions. The model underwent 150 rounds
of steepest descent energy minimization and did not
contain energetically unfavorable bonds, angles or
torsions. The molecular docking model predicted that
the most energetically favorable position for the
m7GpppG molecule is located within the central cavity
between the two main domains of the yeast enzyme
(Figure 3A and B). The
m7GpppG-SpDcp2 docking
model highlighted amino acids that could be involved in
the interaction of the cap structure in the catalytic pocket
of SpDcp2 (Figure 3C). Four of the eight residues high-
lighted by molecular docking (Lys129, Glu147, Gln169,
Tyr220) were previously mutated in SpDcp2 and shown
to be important for the activity of the decapping enzyme
(10,24).
According to the similarity between the predicted D10
structure and the SpDcp2 tertiary structure, we
hypothesized that corresponding amino acids could be
found in D10. We further proceeded with alignment of
the amino acid sequences of SpDcp2 and the D10
protein to search for analogous residues in the viral
decapping enzyme (Figure 4A). Using the information
from the SpDcp2 molecular docking and the sequence
alignment, 17 amino acids of the viral decapping enzyme
that could potentially be involved in the interaction with
the cap structure were selected. In order to get further
insights into the global architecture of the active site of
D10 and the position of the 17 residues selected for mu-
tational analysis, we generated a model for the tertiary
structure of the complete viral enzyme (Figure 4B and
C). Amino acids 1–226 of D10 were aligned with the cor-
responding amino acids of SpDcp2 and modeled onto the
SpDcp2 crystal structure to generate the 3D D10 protein
model. The D10 structure obtained is similar to the
SpDcp2 structure, presenting a beta-sheet cap-binding
cavity bordered by the NUDIX motif alpha-helix
(Figure 4B and C). It should be noted that the 17 amino
acids selected for mutational analysis are located in the
potential active site of the D10 decapping enzyme, as
well as in the two alpha-helical sequences closely sur-
rounding the cavity (Figure 4B and C).
Mutational analysis of the D10 catalytic pocket
The importance of the D10 amino acids that potentially
interact with the cap structure was investigated by
generating a series of enzymatic mutants. Each of the 17
amino acids presented in Figure 4 was individually
substituted by alanine, and the mutant polypeptides
were expressed and puriﬁed in parallel with the
wild-type D10 enzyme. Three other mutants (E132A,
E141A, E145A) previously shown to drastically reduce
the decapping activity were used as controls (Figures 4A
and 5A) (7,26). The relative decapping activies of the
mutants were tested on a N7-methyl-cap RNA substrate
and compared with the activity of an equimolar concen-
tration of the wild-type D10. Eight mutations (E99A,
R118A, D120A, K129A, E144A, D167A, K220A,
Y221A) resulted in a strong reduction of the decapping
activity, thereby demonstrating the importance of these
amino acids for the catalytic activity of D10
(Figure 5A). Speciﬁcally, the substitution of residues
A
SpDcp2
R167 R95
Y220
Q169
B
SpDcp2
R95
Y220
R167
E147
K129
C
K127
Q169
R95
R167
M221
Y220
E147
K129
SpDcp2
Figure 3. Molecular docking model for the binding of
m7GpppG to a decapping enzyme. (A) Molecular docking model for the binding of
m7GpppG
to the S. pombe decapping enzyme (SpDcp2, amino acids 1–266). Ribbon diagram looking into the catalytic center of the enzyme with bound
m7GpppG. (B) Side view of the enzyme following a 90  rotation to the right depicting the loop—a helix—loop NUDIX motif to the front. (C) The
numerous amino acids interacting with the
m7GpppG moiety are presented in a close-up view. The atoms of the cap analog are represented in
spheres.
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resulted in a 90% decrease in the decapping activity. The
substitution of the three other amino acids (Asp167,
Lys220 and Tyr221) produced a 75% reduction of the
decapping activity of D10.
Strikingly, ﬁve of the eight mutations signiﬁcantly af-
fecting the decapping activity (Arg118, Asp120, Lys129,
Glu144, Asp167) are positioned in the D10 tertiary struc-
ture model with their side chains pointing towards the
catalytic center of the enzyme (Figure 5B). This observa-
tion led to the premise that some of these amino acids
could be involved in the interaction with speciﬁc compo-
nents of the cap structure substrate. Unfortunately, the
experiments to evaluate the respective roles of these
amino acid residues are limited because of the lack of
decapping activity of the mutant enzymes. Nevertheless,
analysis of the position of the amino acids within the pre-
dicted tertiary structure of D10 and the decapping assay
results allowed us to propose hypotheses for the role of
some of the important amino acids of D10.
Glu144 is located within the alpha-helix of the NUDIX
motif while Lys129 is pointing towards the latter helix
(Figure 5B), suggesting that both these amino acids
could be involved in direct contact with the methylated
guanosine of the cap structure. In contrast, according to
their position in the catalytic pocket, we theorize that
amino acids Arg118 and Asp120 are likely to be
involved in direct interactions with the ﬁrst nucleotide of
the RNA substrate (Figure 5B). Moreover, amino acid
residues Lys220 and Tyr221 appeared to be part of the
alpha-helix running down the back of the D10 tertiary
structure model and could be required for interaction
with the RNA body (Figure 5B). However, binding experi-
ments of a non-capped RNA with the K220A and Y221A
mutants did not show any reduced afﬁnity for RNA
compared to the wild-type enzyme (data not shown).
Additionally, Glu99 is situated at the base of the active
site cavity, pointing away from the substrate binding site
(Figure 5B). It seemed reasonable to imagine that this
residue may be important for the structural integrity of
the protein or the positioning of the alpha-helix of the
NUDIX motif. Circular dichroism experiments were per-
formed to assess these possibilities. The typical
alpha-helical (222nm) and beta-sheet (208nm) peaks of
the far-UV spectra are signiﬁcantly shifted in the case of
the E99A mutation (Figure 5C), compared to the spectra
obtained for the wild-type D10 protein as well as R100A,
R130A and E166A mutants (data not shown). These
results supported the idea that the E99A mutation alters
the structure of the enzyme, which could result in the
observed decrease in decapping activity of the mutant
polypeptide. The last amino acid shown to be important
for the catalytic activity of D10, Asp167, is positioned in
the middle of the binding cavity in the 3D model and
could potentially be involved in the interaction with the
a-o rb-phosphates of the cap structure (Figure 5B). To
evaluate this latter hypothesis, we evaluated whether the
activity of the D167A mutant enzyme could be inhibited
more potently than the wild-type enzyme by nucleotide
analogs with one, two or three phosphates. Interestingly,
a 50% increased inhibition was produced by GDP and
GMP on the decapping activity of the D167A mutant
compared to the wild-type enzyme and the E166A
mutant (Figure 5D). This increased inhibition could be
explained by the presence of contacts between the
Asp167 side chain and the phosphates of the cap in the
wild-type enzyme that are abolished upon substitution of
Asp167 for alanine in the D167A mutant. This loss of
interaction between the phosphates of the cap structure
and the enzyme would weaken the binding of the substrate
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decapping enzyme (SpDcp2) with the corresponding sequences of the vaccinia virus D10 protein. The NUDIX motif sequence is presented in bold.
The positions of the SpDcp2 amino acids interacting with
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GDP and GMP. These results support the suggestion that
Asp167 is involved in the coordination of the phosphates
of the RNA cap structure. In order to demonstrate that
this effect is selective for Asp167, the E166A substitution
mutant was utilized as a control for this experiment and
the levels of inhibition observed in the presence of GTP,
GDP and GMP were comparable to that of the wild-type
D10 (Figure 5D). Overall, these results revealed a number
of amino acids that are required for both substrate inter-
action and structural integrity of the vaccinia virus D10
decapping enzyme.
DISCUSSION
The RNA cap structure has been shown to be recognized
by many enzymes via a stacking interaction between
aromatic residues located within their respective active
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While this canonical cap-recognition mode is shared
between the human eIF4E translation initiation factor,
the mouse CBC and the vaccinia virus 20-O-
methyltransferase VP39, other cap-binding proteins,
such as the NUDIX decapping enzymes, do not harbor
any aromatic residues in the vicinity of their cap-binding
site (10). This observation suggests that decapping
enzymes employ a different mechanism for cap-
recognition. The present study illustrates the non-
canonical cap-recognition mode of the vaccinia virus
D10 decapping enzyme using a combination of nucleo-
tide analogs, molecular modeling, and site-directed
mutagenesis.
The competitive inhibition of the decapping activity of
the D10 protein by various purine analogs led to the iden-
tiﬁcation of speciﬁc features that are important for the
recognition of the cap structure by the viral enzyme. The
requirement for speciﬁc chemical groups on positions 2
and 6 of the purine rings, as well as the importance of
the triphosphate moiety were revealed. However, the
ribose of the methylated guanosine does not seem to be
critical for substrate recognition. Notably, cap-recognition
by both eIF4E and VP39 also occurs without contacts
with the ribose of the cap (33,34). The 6-oxo/6-amino
group of purines has previously been demonstrated to be
important for ATP/GTP recognition by other nucleotide
interacting proteins. Speciﬁcally, ATP hydrolysis by the
West Nile virus NS3 helicase is dependent on the
presence of a hydrogen-bond donor in position 6, while
incorporation of larger substituents at this position results
in steric hindrance for the interaction between the yeast
RNA 50-triphosphatase and its substrate (34,35).
Interestingly, we now demonstrate that a hydrogen-bond
acceptor at position 6 is important for the interaction of
GTP with D10. These results support previous evidences
that proteins have evolved in a varieties of way to recog-
nize the same or very similar substrates (33,36). Moreover,
the ability of GTP to inhibit the decapping reaction was
not affected by modiﬁcations at the 20 and 30 of the ribose,
corresponding to the ribose of the methylated guanosine
of the cap structure. The hydrogen-bond networks sur-
rounding the cap structure in the catalytic pocket of the
two latter enzymes reveals interactions with both the
methylated-guanosine rings and the phosphate groups,
but none with the ribose (33), suggesting that some
similarities are still present between the non-canonical
cap-recognition by D10 and the canonical cap-binding
by eIF4E and VP39.
A previous study demonstrated that the activity of a
D10 recombinant protein fused to the maltose-binding
protein (MBP) was inhibited by methylated nucleotide de-
rivatives (
m7GpppG,
m7GTP,
m7GDP), but no signiﬁcant
inhibition could be observed with non-methylated deriva-
tives (GTP, GDP) (7). In contrast, the recombinant
his-tagged D10 protein used in the current present can
clearly be inhibited by GTP and GDP. The discrepancy
might arise from the presence of the MBP tag which may
affect the ﬂexibility of the active site of the MBP recom-
binant viral enzyme utilized in the previous study.
Moreover, decapping experiments were performed here
in multiple turnover conditions, while previous studies
were done in single turnover, which might also account
for the observed divergences.
By performing alanine mutations of 17 amino acids of
the vaccinia virus D10 decapping enzyme, we identiﬁed
eight novel amino acids that are important for the
decapping activity (Glu99, Arg118, Asp120, Lys129,
Glu144, Asp167, Lys220, Tyr221). The effects of muta-
tions K129A, D167A and Y221A in D10 correlate with
previous mutational analysis of corresponding amino
acids in the yeast S. pombe Dcp2 enzyme. The crystal
structure of SpDcp2 with ATP suggested the interaction
of Lys129, Gln169 and Tyr220 with the bound substrate,
and the individual mutation of these amino acids to
alanine also resulted in a signiﬁcant decrease in decapping
activity for this fungal enzyme (24). We also observed that
the D10 Arg118 and Asp120 residues were required for the
decapping activity of the viral enzyme. However, corres-
ponding amino acids are not found in the SpDcp2 enzyme.
These results underline both similarities and discrepancies
between the amino acids required for cap recognition in
viral and yeast decapping enzymes.
The results from the mutational analysis of the catalytic
center of D10 as well as the data from the probing of the
active site with nucleotide analogs provided us with a
plethora of new informations on important features for
cap-recognition by the viral decapping enzyme. In the
absence of crystallographic data for D10, our generated
structural model and the crystal structures of other
decapping enzymes lead us to postulate the roles in
cap-recognition for some of the residues observed to be
critical for decapping. Previous crystallographic studies on
NUDIX decapping enzymes have revealed that the bound
cap structure stretches through the catalytic center, with
the methylated guanosine positioned over the alpha-helix
of the NUDIX motif (13,24). Accordingly, amino acids
within the NUDIX motif of D10 are likely to be
involved in catalysis by coordination of a water
molecule or metal ions, as demonstrated by previous bio-
chemical characterization of D10 (26), or in the inter-
action with the methylated guanosine of the cap
structure. Moreover, the mutation of either Lys129 or
Glu144, residues of the NUDIX motif, strongly affected
the decapping activity of D10 and these amino acids could
be involved in direct contacts with the cap structure ac-
cording to their relative position in the structural model.
Based on the probing results with nucleotide analogs and
their position in the structural model, it seems reasonable
that the amino group of Lys129 participates in hydrogen
bonding with the 6-oxo group of the methylated guano-
sine of the cap structure, while Glu144 could be involved
in a hydrogen-bond with the 2-amino position (Figure 6).
Additionally, the crystal structure of the yeast Dcp1–Dcp2
complex resolved in the presence of ATP highlights
contacts between the side chain of Gln169 and the
a-phosphate of the ATP molecule. In the current work,
the sequence alignment, tertiary structure modelization
and catalytic activity assays suggest that Asp167 in D10
could play an homologous role to that of Gln169 in
SpDcp2 (Figures 4A and 5A). Moreover, it was
demonstrated that a D10 protein harboring the D167A
Nucleic Acids Research, 2010,Vol.38, No. 21 7607mutation is 50% more readily inhibited by nucleotides
with one or two phosphates than the wild-type enzyme
(Figure 5D). According to these data, we postulate that
Asp167 could be involved in interactions with the
a-phosphate of the cap structure. However, since the
Asp167 harbors a negatively charged side chain, a metal
ion is likely to be making direct contacts with both the
amino acids and the oxygen groups of the phosphate to
allow proper coordination (Figure 6). Furthermore, while
Arg118 and Asp120 present no evident counterparts in
SpDcp2, their relative position in the structural model of
D10 is consistent with a participation in direct interactions
with the ﬁrst base of the RNA. However, this study did
not focus of the characterization of these interactions and
the results could not specify the precise interplay between
these amino acids and the capped RNA. Finally, to
complete the suggested model, the results of our
previous biochemical analysis of the catalytic mechanism
of D10, with the amino acids involved in the coordination
of two metal ions and a water molecule for the hydrolysis
of the cap structure (Glu132, Glu141, Glu145) were also
incorporated (26).
In Dcp2 enzymes, the RNA-binding channel is located
on the dorsal surface of the NUDIX domain (24,37,38).
Even though the D10 protein does not possess the
conserved RNA-binding motif B found in Dcp2 enzymes
(26), the decapping activity of the viral enzyme is still ef-
ﬁciently inhibited by non-capped RNA [data not shown,
(7)] suggesting a strong contribution by the RNA body in
the interaction. While mutations of amino acids Lys220
and Tyr221, located on the dorsal alpha-helix of the
NUDIX domain in our 3D model of D10, resulted in a
decrease in the decapping activity of D10, binding assays
did not support their direct implication in the interaction
with RNA. One could argue that this C-terminal segment
of D10 may be incorrectly folded in our predicted struc-
ture (amino acids 1–226). Furthermore, amino acids
Lys227, Lys229, Lys242 and Lys243 of D10 are not rep-
resented in the generated tertiary structure model and
could be constituents of an RNA-binding channel for
the D10 decapping enzyme. Future mutational analysis
of these amino acids will address this hypothesis.
Although the current study largely focused on the im-
portant features for cap-recognition by the vaccinia virus
D10 protein, inhibition of a viral decapping enzyme
conserved throughout the poxvirus family, including
variola virus, is also of medical relevance (25,39). The im-
portance of D10 for vaccinia virus replication and virion
infectivity suggests that targeting this enzyme with anti-
viral drugs could lead to the inhibition of viral replication
(25,39). Dcp2 enzymes have been shown to be poorly in-
hibited by nucleotide or cap analogs (9,40), and this is also
the case for the second vaccinia virus decapping enzyme,
D9, and the newly discovered African swine fever virus
g5R (11,12). Therefore, inhibitors designed speciﬁcally to
prevent the non-canonical cap binding by D10 would have
low probabilities of also inhibiting other decapping
enzymes or cap-interacting proteins in a cellular context.
Some of the analogs utilized in this work appear as inter-
esting starting molecules for the design of speciﬁc
Figure 6. Model for N7-methyl-cap RNA interaction with D10. (A) Mechanistic model for the cap-recognition and decapping mechanism of the
D10 protein. During cap-recognition, Asp167 is engaged in the coordination of a divalent cation, Lys129 and Glu144 are involved in direct contacts
with the methylated guanosine of the cap, while Arg118 and Asp120 interact with the ﬁrst base of the RNA. In the chemical step, Glu132 and
Glu145 also engage in the coordination of divalent cations, and Glu141 would be required for the polarization of the attacking water molecule
involved in catalysis.
7608 Nucleic Acids Research, 2010,Vol.38, No. 21inhibitors against the viral decapping enzyme. For
example, 20-methyl-oxo GTP potently inhibited the
decapping reaction, while addition of a methyl group in
N1 position of ATP did modify the inhibitory potency
compared to ATP itself. These two modiﬁcations could
be combined to speciﬁcally target D10 and reduce the
off-target effect. The potential of guanosine analogs
against viruses has already been demonstrated by the util-
ization of Ribavirin, Acyclovir and Entecavir respectively
against hepatitis C, herpes virus and hepatitis B infections
(41–44). The type of catalytic pocket probing and struc-
tural modelization as presented in this study opens the
door to the potential development of other effective viral
inhibitors.
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